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1. Introduction 
Gene transfer vectors derived from neurotropic viruses provide a powerful tool for gene 
therapy of a variety of neurological diseases. The lentiviral vector system permits the 
efficient transfer of genes into non-dividing cells in the central nervous system and sustains 
long-term expression of the genes (Naldini et al., 1996; Reiser et al., 1996; Mochizuki et al., 
1998; Mitrophanous et al., 1999). This vector system has been used for gene therapy trials in 
animal models for neurological diseases (for reviews, see Azzouz et al., 2004a; Wong et al., 
2006; Lundberg et al., 2008). Axonal transport in the retrograde direction, as observed in the 
case of some viral vectors, has a considerable advantage for transferring genes into neuronal 
cell bodies situated in regions remote from the injection sites of the vectors (see Fig. 1). 
These viral vectors, when injected into the striatum, deliver the genes through retrograde 
transport into nigrostriatal dopamine neurons that are the major target for gene therapy of 
Parkinson’s disease (Zheng et al., 2005; Barkats et al., 2006). Intramuscular injection of the 
vectors also delivers retrogradely the genes into motor neurons that are the target for gene 
therapy of motor neuron diseases (Baumgartner & Shine, 1998; Perrelet et al., 2000; 
Mazarakis et al., 2001; Sakamoto et al., 2003; Azzouz et al., 2004b).  
To enhance the gene transfer of a human immunodeficiency virus type-1 (HIV-1)-based 
vector via retrograde transport, we have previously generated the HIV-1 vector 
pseudotyped with a selective variant of rabies virus glycoprotein (RV-G) (Kato et al., 2007). 
Injection of this RV-G-pseudotyped vector into the mouse striatum yields an increase in 
gene transfer into neuronal populations in the cerebral cortex, thalamus, and ventral 
midbrain, each of which innervates the striatum. Injection of the RV-G pseudotype into the 
monkey striatum (caudate and putamen) results in increased gene transfer into the 
nigrostriatal dopamine neurons. The RV-G pseudotyping of the HIV-1 vector enhances the 
efficiency of gene transfer through retrograde axonal transport in the rodent and nonhuman 
primate brains. However, because large-scale application of gene therapy trials requires 
www.intechopen.com
 Viral Gene Therapy 
 
372 
high-titer stocks of the vector, a lentiviral vector system that produces more efficient 
retrograde gene transfer is needed. 
Recently, we developed a novel vector system for highly efficient retrograde gene transfer 
(designated as HiRet vector) by pseudotyping the HIV-1 vector with fusion glycoprotein B 
type (FuG-B), in which the cytoplasmic domain of RV-G was substituted by the 
corresponding part of the vesicular stomatitis virus glycoprotein (VSV-G) (Kato et al., 2011).  
The HiRet vector shifts the transducing property of the lentiviral vector and promotes the 
retrograde gene transfer into different brain regions innervating the striatum with greater 
efficiency than that of the RV-G pseudotype in both rodent and nonhuman primate brains. 
In the present chapter, we describe the development and property of the HiRet vector as 
well as the retrograde gene transfer of the vector into target neurons for gene therapy of 
neurological diseases, such as Parkinson’s and motor neuron diseases. 
 
 
Fig. 1. Schematic illustration of gene transfer process through retrograde axonal transport.  
The viral vectors enter synaptic terminals and are transported within axons in the 
retrograde direction to neuronal cell bodies where transgene expression is induced. 
2. Development and characterization of HiRet vector 
2.1 Pseudotyping with fusion envelope glycoprotein 
To develop the HiRet vector, we tested two kinds of fusion glycoprotein (termed FuG-A and 
FuG-B), both of which are composed of the RV-G and VSV-G segments, for the 
pseudotyping of the HIV-1 vector. FuG-A contains the extracellular domain of RV-G fused 
to the transmembrane and cytoplasmic domains of VSV-G, whereas FuG-B contains the 
extracellular and transmembrane domains of RV-G connected to the VSV-G cytoplasmic 
domain (Fig. 2A). HIV-1-based lentiviral vectors carrying transgene encoding green 
fluorescent protein (GFP) were produced by pseudotyping with RV-G, FuG-A, or FuG-B. 
When the functional titer (transducing unit) in HEK293T cells was measured by flow 
cytometry, the titer of the FuG-B pseudotype was 13 times greater than that of the RV-G 
pseudotype, whereas the titer of the FuG-A pseudotype in this cell line showed only a 
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moderate increase compared with the RV-G vector titer (Fig. 2B). The functional titer of the 
FuG-B pseudotype, when measured in neuronal cell lines (Neuro2A and N1E-115 cells), was 
also the highest among the three vector pseudotypes (Fig. 2B). In contrast, the concentration 
of physical particles (or RNA copy number) of the vectors, when estimated by quantitative 
reverse transcription-PCR analysis, showed no remarkable change among the three 
pseudotypes (data not shown). Therefore, the HIV-1 vector pseudotyped with FuG-B 
exhibited a greatly increased efficacy of transduction into cultured cells. 
 
 
Fig. 2. Production of vector pseudotypes with fusion glycoproteins. 
(A) Structure of the fusion glycoproteins FuG-A and FuG-B composed of different 
combinations of the N-terminal and C-terminal segments from RV-G and VSV-G. Amino 
acid sequences around the junction (arrowhead) between the RV-G and VSV-G segments 
are indicated. S, signal peptide; TM, transmembrane domain. (B) Functional titer of the 
vector pseudotypes. HEK293T cells (eighteen 10-cm-diameter tissue culture dishes) were 
transfected, and the conditioned medium was collected. Vector particles were pelleted by 
ultracentrifugation and resuspended in PBS (1 ml). HEK293T, Neuro2A, and N1E-115 cells 
were transduced with viral vectors, and the functional titer was determined by flow 
cytometry. Values were obtained from four independent experiments. *p < 0.001, significant 
difference from the titer of the RV-G or FuG-A pseudotype (ANOVA, Tukey HSD test). 
(Data from Kato et al., 2011) 
2.2 Promoted efficiency of retrograde gene transfer 
To characterize the in vivo gene transfer of the pseudotyped lentiviral vectors, we injected 
the vectors into the dorsal striatum of mice, and studied gene expression in the brain regions 
that innervate the striatum, including the primary motor cortex (M1), primary 
somatosensory cortex (S1), parafascicular thalamic nucleus (PF), and substantia nigra pars 
compacta (SNc). The number of GFP-positive cells in each brain region was prominently 
increased in the FuG-B vector-injected mice over that in the RV-G vector-injected mice  
(Fig. 3A); and the increases in the cell number were 12-, 12-, 8-, and 14-fold in the M1, S1, PF, 
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and SNc, respectively (Fig. 3B). In contrast, the cell number in each brain region was 
comparable between the FuG-A and RV-G vector-injected animals (Fig. 3A, B). Therefore, 
the FuG-B pseudotyping of the HIV-1 vector greatly enhanced the efficiency of retrograde 
gene transfer into the brain regions innervating the dorsal striatum. Based on these in vivo 
data, we designated the FuG-B pseudotype as the HiRet vector.  
In the HiRet vector, the cytoplasmic domain of RV-G was substituted by the corresponding 
part of VSV-G, which resulted in the enhancement of transduction of cell lines and  
 
 
Fig. 3. Efficiency of retrograde gene transfer by the pseudotyped vectors. 
Lentiviral vectors pseudotyped with RV-G, FuG-A or FuG-B with equivalent copy numbers 
of viral RNA (1.2 x 1010 copies/ml, 1.0 µl x 2 sites) were injected into the mouse striatum, 
and four weeks later sections were used for GFP immunostaining. (A) Transgene expression 
through retrograde transport in the primary motor cortex (M1), primary somatosensory 
cortex (S1), parafascicular thalamic nucleus (PF), and substantia nigra pars compacta (SNc). 
fr, fasciculus retroflexus. Scale bars: 200 µm. (B) The cell number in the various brain 
regions. The number of GFP-positive cells per section was counted (n = 4). *p < 0.01, **p < 
0.001, significant differences from the RV-G or FuG-A pseudotype (ANOVA/Tukey HSD 
test). (Data from Kato et al., 2011) 
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retrograde gene transfer. The cytoplasmic domain differs in length between RV-G (44 amino 
acids) and VSV-G (29 amino acids), and their amino acid sequences do not show any 
particular homology (Rose et al., 1982). To test whether the length of the cytoplasmic 
sequence may be involved in the enhancement of retrograde gene transfer, we constructed 
deletion mutants of the RV-G cytoplasmic domain consisting of 10 or 20 amino acids, and 
used them for the pseudotyping of the HIV-1 vector. Analysis of the in vivo gene transfer 
indicated that shorter cytoplasmic domain of RV-G increased the efficiency of gene transfer 
through retrograde transport, but that the VSV-G cytoplasmic domain induced most 
efficiently the retrograde gene transfer (data not shown). The results suggest the importance 
of both the length and sequence of the glycoprotein cytoplasmic domain in the retrograde 
gene transfer of the HiRet vector. Based on our titration experiments using the pseudotyped 
vectors, the viral RNA titration displayed no significant change in the yield of physical 
particles between the pseudotyped vectors. Modification of the cytoplasmic domain of a 
viral glycoprotein thus seemed to shift the property of gene transduction of the 
pseudotyped vectors into the host cells, although the efficacy of formation or budding of the 
particles appeared to be unaffected. 
The host range of lentiviral vectors is altered by pseudotyping with distinct envelope 
glycoproteins (for review, see Cronin et al., 2005). RV-G interacts with certain neuronal 
receptors, such as the nicotinic acetylcholine receptor α-subunit, low-affinity nerve growth 
factor receptor, and neural cell adhesion molecule (Hanham et al., 1993; Gastka et al., 1996; 
Thoulouze et al., 1998; Tuffereau et al., 1998). Substitution of the cytoplasmic domain of a 
viral glycoprotein may influence incorporation of the glycoprotein into vector particles or 
cause conformational changes in the glycoprotein structure involved in binding to receptor 
molecules or membrane fusion of the pseudotyped vector. These changes may affect the 
mechanism involved in vector entry into synaptic terminals or the transduction level of the 
vector, resulting in the enhanced retrograde gene transfer.  
3. Retrograde gene delivery by HiRet vector into target neurons for gene 
therapy 
3.1 Nigrostriatal dopamine neurons 
We investigated the capability of the HiRet vector to introduce retrograde gene transfer into 
target neurons for gene therapy of neurological diseases. Nigrostriatal dopamine neurons 
are the major target for the therapy of Parkinson’s disease (Zheng et al., 2005; Barkats et al., 
2006). Retrograde gene transfer of the HiRet vector into the dopamine neurons in the mouse 
SNc was less efficient, although transfer of the vector into cortical and thalamic neurons was 
greatly increased (see Fig. 3). We thus tested the retrograde gene transfer of the HiRet vector 
into the SNc of the monkey. The pseudotyped vectors were injected into the striatum 
(caudate nucleus and putamen) of crab-eating monkeys, and sections through the SNc were 
stained immunohistochemically for GFP. Injection of the HiRet vector (FuG-B pseudotype) 
resulted in the appearance of a larger number of GFP-positive cells in the SNc as compared 
with that of the RV-G pseudotype (Fig. 4A), and the increase was 10-fold of the RV-G 
pseudotype control (Fig. 4B). The GFP transgene was expressed in a majority of the 
dopamine neurons (74.8%, n = 2), which were identified by immunostaining for tyrosine 
hydroxylase (TH), a key enzyme of dopamine biosynthesis (Fig. 4C). The HiRet vector thus 
achieved highly efficient delivery of genes through retrograde transport into the 
nigrostriatal dopamine system in the nonhuman primate brain. 
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Fig. 4. Retrograde gene transfer into nigrostriatal dopamine neurons. 
Lentiviral vectors pseudotyped with RV-G or FuG-B with equivalent copy numbers of viral 
RNA (8.5 x 109 copies/ml, 7.5 µl x 14 sites) were stereotaxically injected into the caudate and 
putamen, and four weeks later a series of sections were used for histological analysis. (A) 
GFP staining of sections through the SNc. Photos at the right denote magnified views of the 
rectangular boxes in the left ones. (B) Average number of GFP-positive cells per SNc section 
(n = 2). (C) Double immunofluorescence staining for GFP and TH in the SNc. GFP-positive 
signals, TH-positive signals, and merged images are presented in green, red, and yellow, 
respectively. SNr, substantia nigra pars reticulata. Scale bars, 1 mm (A) and 50 µm (C). 
(Data from Kato et al., 2011) 
3.2 Hindbrain/spinal motor neurons 
Motor neurons are the target for gene therapy of motor neuron diseases (Baumgartner & 
Shine, 1998; Perrelet et al., 2000; Mazarakis et al., 2001; Sakamoto et al., 2003; Azzouz et al., 
2004b). Therefore, we studied retrograde gene transfer of the HiRet vector into motor 
neurons in the hindbrain and spinal cord. The vector was injected into the tongue or 
hindlimb muscles in mice, and sections through the hindbrain (hypoglossal nerve) or spinal 
cord (lumbar level) were stained for GFP immunohistochemistry. Such injections labeled 
cells in the hypoglossal nucleus of the posterior hindbrain and in the ventral horn of the 
spinal cord at the lumbar level (Fig. 5A). Double immunofluorescence histochemistry for 
GFP and the motor neuronal marker choline acetyltransferase confirmed GFP expression in 
the hypoglossal and spinal motor neurons that innervate the injected muscles (Fig. 5B). The 
HiRet vector thus enabled us to induce retrograde gene delivery into motor neurons. The 
extent of motor neuron transfer of the HiRet vector will be compared with that of the RV-G 
pseudotype elsewhere. 
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The lentiviral vector system based on HIV-1 has been extensively applied to gene therapy 
trials for neurological diseases. Retrograde axonal transport of viral vectors offers a great 
advantage to the delivery of genes into neuronal cell bodies that are located in brain areas 
distant from the injection site. The pseudotyping of HIV-1-based vectors with selective 
variants of RV-G increases gene transfer via retrograde transport into the central nervous 
system. Since the large-scale application for gene therapy trials requires high-titer stocks of 
the vector, the pseudotyping of a lentiviral vector that generates a greater efficiency of 
retrograde transport was needed. Therefore, we developed the HiRet vector for highly 
efficient retrograde gene transfer by pseudotyping an HIV-1 vector with a fusion envelope 
glycoprotein FuG-B, in which the cytoplasmic domain of RV-G was substituted by the 
corresponding part of VSV-G. The HiRet vector shifted the transducing property of the  
 
 
Fig. 5. Retrograde gene transfer into motor neurons. 
(A) GFP expression in the hindbrain and spinal cord after the FuG-B vector injection  
(2.4 X 109 transduction units/ml). Sections through the posterior hindbrain containing the 
hypoglossal nucleus and the lumbar spinal cord were prepared from the injected animals 
and stained by using GFP immunohistochemistry. (B) GFP expression in motor neurons. 
The sections were used for double immunofluorescence staining for GFP and choline 
acetyltransferase (ChAT), a marker of motor neurons. GFP-positive signals, ChAT-positive 
signals, and merged images are shown in green, red, and yellow, respectively. cc, central 
canal. Scale bar: 50 µm. 
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lentiviral vector and enhanced the retrograde transport-mediated gene transfer into 
different brain regions. In particular, its transfer efficiency into the brain regions innervating 
the striatum attained 8- to 14-fold increases over the efficiency of the RV-G pseudotype. In 
addition, intrastriatal injection of the HiRet vector in the monkey brain resulted in gene 
transfer into a large number of nigrostriatal dopamine neurons that are the major target for 
gene therapy of Parkinson’ disease. Furthermore, intramuscular injection of the HiRet vector 
achieved gene transfer into motor neurons in the hindbrain and spinal cord that are the 
target for gene therapy of motor neuron diseases. Our strategy with the HiRet vector 
provides a powerful tool for the treatment of certain neurological diseases by promoting 
retrograde gene delivery of this viral vector. 
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